PI3K pathway in NSCLC

Frontiers in Oncology

Volumn 1, Issue JAN, 2012, Pages

  Martinez Martí, Alex ^a   Felip, Enriqueta ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Copy number; Exon 20; Exon 9; Gene amplification; Mutations; NSCLC; P110a; PI3KCA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN P85; UNCLASSIFIED DRUG;

CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS; DNA SEQUENCE; GENE AMPLIFICATION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

EID: 84879682882     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2011.00055     Document Type: Short Survey

References (35)

1. Angulo, B., Conde, E., Suarez-Gauthier, A., Garcia-Lujan, R., Sanchez-Cespedes, M., Lopez-Encuentra, A., Paz-Ares, L., and Lopez-Rios, F. (2011). PIK3CA alterations in lung squamous cell carcinomas: role for mutations and amplification. IASLC. abstr. 037.06, Amsterdam.
2. Barroso, I., Luan, J., Middelberg, R. P. S., Harding, A. H., Franks, P. W., Jakes, R. W., Clayton, D., Schafer, A. J., O'Rahilly, S., and Wareham, N. J. (2003). Candidate gene association study in type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biol. 1, e20. doi:10.1371/journal.pbio.0000020
3. Cantley, L. C. (2002). The phosphoinositide 3-kinase Pathway. Science 296, 1655-1657.
4. Carcereny, E., Molina, M. A., Sanchez, J. J., Bertran-Alamillo, J., Mayo, C., Aldeguer, E., Gimenez-Capotan, A., Yeste, Z., Costa, C., Benlloch, S., Martinez, A., Buges, C., Bosch, J., Isla, D., Domine, M., Provencio, M., Sanchez, J. M., Camps, C., Taron, M., and Rosell, R. (2011). Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-samll-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. J. Clin. Oncol. 29(Suppl.) abstr. 7588.
5. Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., and Cantley, L. C. (1993). Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-KDa subunit. J. Biol. Chem. 268, 9478-9483.
6. Courtney, K. D., Corcoran, R. B., and Engelman, J. A. (2010). The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075-1083.
7. Engelman, J. A., Luo, J., and Cantley, L. C. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619.
8. Engelman, J. A., and Settleman, J. (2008). Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73-79.
9. Franke, T. F., Kaplan, D. R., Cantley, L. C., and Toker, A. (1997). Direct regulation of the AKT proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275, 665-668.
10. Fruman, D. A., Meyers, R. E., and Cantley, L. C. (1998). Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481-507.
11. Gymnopoulos, M., Elsliger, M. A., and Vogt, P. K. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci U.S.A. 104, 5569-5574.
12. Hansen, T., Andersen, C. B., Echwald, S. M., Urhammer, S. A., Clausen, J. O., Vestergaard, H., Owens, D., Hansen, L., and Pedersen, O. (1997). Identification of a common amino acid polymorphism in the p85α regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 46, 494-501.
13. Huang, C. H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., and Amzel, M. (2007). The structure of a human p110a/p85a complex elucidates the effects of oncogenic PI3K mutations. Science 318, 1744-1748.
14. Ikenoue, T., Kanai, F., and Hikiba, Y. (2005). Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562-4567.
15. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675.
16. Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., and Fujii, Y. (2006). PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54, 209-215.
17. Kawano, O., Sasaki, H., Okuda, K., Yukiue, H., Yokoyama, T., Yano, M., and Fujii, Y. (2007). PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58, 159-160.
18. Kirwan, J., Varastehpour, A., Jing, M., Presley, L., Shao, J., Friedman, J. E., and Catalano, P. M. (2004). Reversal of insulin resistance postpartum in linked to enhanced skeletal muscle insulin signalling. J. Clin. Endocrinol. Metab. 89, 4678-4684.
19. Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., and Lee, S. H. (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477-1480.
20. Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F. R., Siggillino, A., Flacco, A., Baldelli, E., Iacono, D., Mameli, M. G., Cavaliere, A., and Crino, L. (2011). Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 6, 707-715.
21. Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., and Kelsey, K. T. (2005). PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 36, 768-776.
22. Massion, P. P., Kuo, W. L., Stokoe, D., Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., Albertson, D. G., Jablons, D. M., and Gray, J. W. (2002). Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res. 62, 3636-3640.
23. Okudela, K., Sukuki, M., Kageyama, S., Bunai, T., Nagura, K., Igarashi, H., Takamochi, K., Suzuki, K., Yamada, T., Niwa, H., Ohashi, R., Ogawa, H., Mori, H., Kitamura, H., Kaneko, T., Tsuneyoshi, T., and Sugimura, H. (2007). PIK3CA mutation and amplification in human lung cancer. Pathol. Int. 57, 664-671.
24. Richardson, C. J., Schalm, S. S., and Blenis, J. (2004). PI3-kinase and TOR: PIKTORing cell growth. Semin. Cell Dev. Biol. 15, 147-159.
25. Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., Delong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573.
26. Samuels, Y., and Velculescu, V. E. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224.
27. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2004). High frequency of mutations of the PIK3CA gene in human cancer. Science 304, 554.
28. Sarbassou, D., Guertin, D. D., Ali, S. M., and Sabatini, D. M. (2005). Phosphorylation and regulation of AKT/PKB by the rector-mTOR complex. Science 307, 1098-1101.
29. Shaw, R. J., and Cantley, L. C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430.
30. Skolnik, E. Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. (1991). Cloning of PI3Kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65, 83-90.
31. Vanhaesebroeck, B., and Waterfield, M. D. (1999). Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253, 239.
32. Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
33. Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Date, H., Lam, W. L., Minna, J. D., and Gazdar, A. F. (2008). PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913-6921.
34. Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer. Variations on a theme. Oncogene 27, 5497-5510.
35. Zhao, L., and Vogt, P. K. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496.